Ashkan Roozitalab

Dr. Ashkan Roozitalab

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2025 in Viruses
Verified
Journal Article
Open access
PDF file
ARAshkan Roozitalab
Ashkan Roozitalab
JZJiantao Zhang
Jiantao Zhang
CZChenyu Zhang
Chenyu Zhang
QTQiyi Tang
Qiyi Tang
Richard Y ZhaoRichard Y Zhao
Richard Y Zhao
Zika virus (ZIKV) was first discovered in Uganda’s Zika Forest in 1947. The early African viruses posed little or no health risk to humans. Since then, ZIKV has undergone extensive genetic evolution and adapted to humans, and it now causes a range of human diseases, including neurologically related diseases in adults and congenital malformations such as microcephaly in newborns. This raises a critical question as to why ZIKV has become pathogenic to humans, and what virological changes have taken place and enabled it to cause these diseases? This review aims to address these questions. Specifically, we focus on the ZIKV envelope (E) protein, which is essential for initiating infection and plays a crucial role in viral entry. We compare various virologic attributes of E protein between the ancestral African strains, which presumably did not cause human diseases, with epidemic strains responsible for current human pathogenesis. First, we review the role of the ZIKV E protein in viral entry and endocytosis during the viral life cycle. We will then examine how the E protein interacts with host immune responses and evades host antiviral responses. Additionally, we will analyze key differences in the sequence, structure, and post-translational modifications between African and Asian lineages, and discuss their potential impacts on viral infection and pathogenesis. Finally, we will evaluate neutralizing antibodies, small molecule inhibitors, and natural compounds that target the E protein. This will provide insights into the development of potential vaccines and antiviral therapies to prevent or treat ZIKV infections and associated diseases.

24 February 2013 in Comparative Clinical Pathology
Verified
Journal Article
Closed access
PDF file
AHAmin Haghani
Amin Haghani
ARAshkan Roozitalab
Ashkan Roozitalab
SSSeyedeh Nikoo Safi
Seyedeh Nikoo Safi

19 July 2025 in Pathogens
Verified
Journal Article
Open access
PDF file
ARAshkan Roozitalab
Ashkan Roozitalab
CZChenyu Zhang
Chenyu Zhang
JZJiantao Zhang
Jiantao Zhang
GLGe Li
Ge Li
CYChengyu Yang
Chengyu Yang
Richard Y ZhaoRichard Y Zhao
Richard Y Zhao
The 2016 Zika virus (ZIKV) epidemic has largely subsided, but a key question remains. How did ZIKV evolve to become a virulent human pathogen compared to the virus of its original discovery? What specific virologic and pathologic changes contributed to increased pathogenicity in humans? Phylogenetic studies have identified two genetically distinct ZIKV, the African and Asian lineages, which differ in their pathogenicity. Previous studies including ours suggest that the envelope (E) protein plays a key role in viral entry, immune activation, and neuropathogenesis. This study aimed to further elucidate virologic and pathogenic differences between these lineages by assessing their ability to bind and replicate in host cells, induce apoptotic cell death, trigger inflammatory responses, and influence human neural progenitor cell (hNPC)-derived neurosphere formation. We compared a historic African ZIKV strain (MR766) with an epidemic Brazilian strain (BR15) and evaluated the effects of the E protein inhibitor quercetin-3-β-O-D-glucoside (Q3G) and an E protein-neutralizing antibody (AbII). Our results revealed distinct virologic properties and that MR766 exhibited stronger inhibition of neurosphere formation due to enhanced viral binding to neuronal SH-SY5Y cells, while BR15 infection triggered a heightened pro-inflammatory cytokine response with reduced viral binding. Chimeric virus studies suggested that the E protein likely influences viral binding, replication efficiency, immune activation, and neuropathogenesis. Notably, Q3G exhibited antiviral activities against both MR766 and BR15, whereas AbII preferentially inhibited MR766. These findings highlight the virological differences between ancestral and epidemic viral strains, as well as the critical role of E protein in viral permissiveness, immune response, and neuropathogenesis, providing insights for developing targeted antiviral strategies.

10 April 2025 in Microbiology Resource Announcements
Verified
Journal Article
Open access
OEOla K. Elsakhawy
Ola K. Elsakhawy
ARAshkan Roozitalab
Ashkan Roozitalab
Mohamed AbouelkhairMohamed Abouelkhair
Mohamed Abouelkhair
We report the genome sequence of a strain belonging to the species Tetraparvovirus ungulate 1 (hereafter referred to as UTPV1-1882), identified in a 4-month-old cow with respiratory disease in Tennessee, USA. The sequence data will improve the existing genomic database, which currently lacks information on these viruses in the United States.

9 January 2026 in Pathogens
Verified
Journal Article
Open access
PDF file
ARAshkan Roozitalab
Ashkan Roozitalab
CZChenyu Zhang
Chenyu Zhang
JZJiantao Zhang
Jiantao Zhang
GLGe Li
Ge Li
CYChengyu Yang
Chengyu Yang
Richard Y ZhaoRichard Y Zhao
Richard Y Zhao
The authors emphasize on the long-standing codon adaptation of African ZIKV lineages to primate hosts, as this evolutionary framework helps explain several characteristics of African strains

12 June 2025 in Microbiology Resource Announcements
Verified
Journal Article
Open access
OEOla K. Elsakhawy
Ola K. Elsakhawy
ARAshkan Roozitalab
Ashkan Roozitalab
Mohamed AbouelkhairMohamed Abouelkhair
Mohamed Abouelkhair
We report the genome sequence of a bovine respiratory syncytial virus strain (hereafter referred to as BRSV_23), identified in a cow in Tennessee. This genome sequence updates the currently circulating BRSV field strains in the United States, providing insights into viral evolution and epidemiology to improve diagnostics and control strategies.